Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC in Treatment of Adult Upper Limb Spasticity and Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC
Sponsor: Solstice Neurosciences
A PHASE2/PHASE3 clinical study on Cerebral Palsy and Cerebrovascular Accident, this trial is ongoing. The trial is conducted by Solstice Neurosciences and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
7 versions recorded-
Apr 2025 — Present [monthly]
Unknown PHASE2/PHASE3
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Apr 2023 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Sep 2021 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Solstice Neurosciences
- Supernus Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Boise, United States
- • Bradenton, United States
- • Brno, Czechia
- • Dallas, United States
- • Downey, United States
- • Nashville, United States
- • Port Royal, United States
- • Prague, Czechia
- • Stamford, United States